| 000 | 01603 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250513171058.0 | ||
| 264 | 0 | _c19990527 | |
| 008 | 199905s 0 0 eng d | ||
| 022 | _a0142-2782 | ||
| 024 | 7 |
_a10.1002/(sici)1099-081x(199901)20:1<19::aid-bdd152>3.0.co;2-q _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOlling, M | |
| 245 | 0 | 0 |
_aBioavailability of carbamazepine from four different products and the occurrence of side effects. _h[electronic resource] |
| 260 |
_bBiopharmaceutics & drug disposition _cJan 1999 |
||
| 300 |
_a19-28 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 |
_aAnticonvulsants _xadverse effects |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aChromatography, High Pressure Liquid |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 |
_aDiethylcarbamazine _xadverse effects |
| 650 | 0 | 4 |
_aDrugs, Generic _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLipoxygenase Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aTherapeutic Equivalency |
| 700 | 1 | _aMensinga, T T | |
| 700 | 1 | _aBarends, D M | |
| 700 | 1 | _aGroen, C | |
| 700 | 1 | _aLake, O A | |
| 700 | 1 | _aMeulenbelt, J | |
| 773 | 0 |
_tBiopharmaceutics & drug disposition _gvol. 20 _gno. 1 _gp. 19-28 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/(sici)1099-081x(199901)20:1<19::aid-bdd152>3.0.co;2-q _zAvailable from publisher's website |
| 999 |
_c10046585 _d10046585 |
||